Accessibility Menu
CytomX Therapeutics Stock Quote

CytomX Therapeutics (NASDAQ: CTMX)

$3.39
(-6.2%)
-0.23
Price as of October 22, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$3.39
Daily Change
(-6.2%) $0.23
Day's Range
$3.25 - $3.62
Previous Close
$3.39
Open
$3.6
Beta
1.08
Volume
3,785,294
Average Volume
3,546,676
Market Cap
559.1M
Market Cap / Employee
$3.39M
52wk Range
$0.4 - $3.91
Revenue
-
Gross Margin
0.99%
Dividend Yield
N/A
EPS
$0.57
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

CytomX Therapeutics Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
CTMX+208.18%-49.85%-12.89%-74%
S&P+15.06%+95.03%+14.29%+235%

CytomX Therapeutics Company Info

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$18.66M-25.7%
Gross Profit$18.31M-25.7%
Gross Margin98.14%0.0%
Market Cap$357.62M276.2%
Market Cap / Employee$2.96M0.0%
Employees121-0.8%
Net Income-$0.15M97.6%
EBITDA-$0.94M88.3%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$49.04M13.4%
Accounts Receivable$1.87M-32.6%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$1.44M-79.1%
Short Term Debt$5.44M12.0%

Ratios

Q2 2025YOY Change
Return On Assets28.71%22.7%
Return On Invested Capital55.52%195.4%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$15.78M19.7%
Operating Free Cash Flow-$15.75M19.4%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Earnings6.952.621.283.97-54.66%
Price to Book-3.94-3.44-111.747.31-378.43%
Price to Sales0.790.600.382.08139.77%
Price to Tangible Book Value-3.69-3.22-25.627.77-411.46%
Enterprise Value to EBITDA-1.42-0.48-0.71-151.01-5616.19%
Return on Equity108.2%-
Total Debt$10.60M$9.39M$8.15M$6.89M-41.38%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.